ImmunoVaccine Wins Japanese Patent for Vaccine Technology
Posted on: Wednesday, 6 August 2008, 12:00 CDT
ImmunoVaccine Technologies, a vaccine development company, has received patent approval from the Japanese Patent Office for its vaccine platform.
The specific patent, vaccines with enhanced immune response and methods for their preparation, claims broad exclusivity that an effective, long-term immune response to treat a disease can be produced using a vaccine comprising of an antigen, an adjuvant, vesicles known as liposomes, and a hydrophobic carrier.
Securing broad patent coverage is said to be part of ImmunoVaccine Technologies's (IVT) strategy to maximize the market potential of its VacciMax platform in the pharmaceutical markets in the world; including the US, Europe, Canada, Australia and Japan.
The company's VacciMax technology is based on a novel approach to the use of liposomes in an oil emulsion. IVT has discovered that liposomes, stabilized in the VacciMax technology, significantly enhance antibody production, creating a more rapid immune response, following a single vaccination.
Randal Chase, president and CEO of IVT, said: "The issuance of the patent in Japan complements the US and European patents for our vaccine platform technology. We are watching the growth of the Asian market, and patent coverage in Japan is an important step in contributing to the wide reach of our vaccine products."
Source: Datamonitor
Related Articles
- Swine Flu Vaccine Trial Shows One Dose Gives 'Strong Immune Response'
- Brightcove Announces General Availability of Fully-Localized Online Video Platform in Japan
- Vical Pandemic Influenza Vaccines Achieve T-Cell Responses and Cross-Clade Reactivity in Humans
- Nasal Vaccine for Smallpox Confers High Levels of Immunity Without Safety Risks
- CEL-SCI Announces Issuance of U.S. Patent for New Platform Technology to Treat Immune System-Based Diseases
- CEL-SCI Announces the Development and Patenting of a New Platform Technology to Treat Immune System-Based Diseases
- HPV Vaccine Nearing Approval: FDA Likely to OK Immunizer That May Eliminate Most Cases of Cervical Cancer
- Dynavax Scientist Receives 'European Inventor of the Year' Award From European Patent Office for Vaccine Production Platform
- U3 Extends Smart Drive Computing Platform to Japan
- XYOTAX Patent Allowance Provides Exclusivity in Japan Until 2018
 |
 |
User Comments (0)
RSS Feeds